TFDA Approves CEMMA and LipoCoat Coated Antifouling CVC Catheter
Regulatory Approval Milestone in Taiwan
Jasper van Weerd
May 28, 2025
Introduction
TFDA approves CEMMA and LipoCoat co-developed coated antifouling central venous catheter. TFDA Approval Press ReleaseTaipei / Enschede, May 28, 2025 — CEMMA Medical and LipoCoat announce medical device approval by the Taiwan Food and Drug Administration (TFDA) for their antifouling CVC catheter featuring LipoCoat's non-antibiotic lipid coating.
TFDA Approval Press ReleaseTaipei / Enschede, May 28, 2025 — CEMMA Medical and LipoCoat announce medical device approval by the Taiwan Food and Drug Administration (TFDA) for their antifouling CVC catheter featuring LipoCoat's non-antibiotic lipid coating.
References
TFDA Approval Registration Details
Jasper van Weerd
CEO / Founder
Jasper van Weerd is CEO of Lipocoat Group and founder of the LipoCoat® coating technology, translating lipid-based science into products that improve the safety, comfort and performance of medical devices.
Explore Partnership Opportunities
Connect with our business development team to discuss OEM partnerships and regulatory strategy.
